More weight-loss drugs could be offered as part of new diabetes care
Summary
The National Institute for Health and Care Excellence (NICE) has suggested more people with type 2 diabetes in England, Wales, and Northern Ireland should have access to new medicines, including weight-loss drugs, for personalized treatment. This recommendation is aimed at reducing complications like heart disease and potentially saving costs and lives. The new guidance suggests using specific diabetes drugs, such as SGLT-2 inhibitors and GLP-1 agonists, as first-choice treatments.Key Facts
- NICE suggests that type 2 diabetes treatment should be more personalized rather than one-size-fits-all.
- Newer drugs, including weight-loss ones, could be used more widely to prevent complications like heart disease and strokes.
- About 4.6 million people in the UK have diabetes, with 90% having type 2.
- SGLT-2 inhibitors are recommended as a first-choice treatment for diabetes, benefiting heart and kidney health while lowering blood sugar.
- Currently, only 20% of patients with type 2 diabetes and heart issues receive these recommended medications.
- NICE indicates that equitable access to these drugs is a concern, especially for women, older adults, and black people.
- GLP-1 agonists such as semaglutide and liraglutide, known for aiding weight loss, may be prescribed to additional 750,000 people.
- The guidelines aim to reduce health inequalities and focus on preventing illnesses proactively.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
